Cancer in connective tissue disease
β Scribed by K. A. Black; P. J. Zilko; R. L. Dawkins; B. K. Armstrong; G. L. Mastaglia
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 300 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
β¦ Synopsis
The risk of cancer appears to be increased in polymyositis (PM) although not all agree with this interpretation (1-5). In other related diseases the risk is probably lower (6-9) but there has not been assessment in mixed connective tissue disease (MCTD). Since it is now possible to separate mixed connective tissue disease from polymyositis, systemic lupus erythematosus (SLE), and progressive systemic sclerosis (PSS), at least serologically, it should be possible to determine whether the increased risk applies to mixed connective tissue disease, polymyositis, or neither.
We used strict criteria (10-14) to classify patients followed in a single center. After allowing for age, sex, and years of followup, we compared cancer rates with those found in an Australian population.
π SIMILAR VOLUMES
## Background: To determine the prevalence of connective tissue disease in a cohort of individuals with silicosis, we reviewed the medical records and questionnaires from individuals reported from 1987 to 1995 to a state surveillance system for silicosis. Reporting of individuals with silicosis is
Three patients are described in whom autoimmune connective tissue disease developed within 2% years after cosmetic mammary augmentation with silicone gel-filled, elastomer envelope-type prostheses. Comparison is made with previously reported cases concerning the complications after paraffin and proc
alleles may actually operate against its formation. Alternatively, it is possible that immune response genes which promote antibodies to nRNP may not be represented on DRZlMBl/MTl and DR3/MT2 bearing haplotypes. Thus, the presence of both sets of alleles, as seen in our patients, might exclude this